These findings provide initial evidence supporting the therapeutic potential of FLRL2-mediated gene modification in NAFLD and underscore the prospective utility of targeting FLRL2 and the Arntl-Sirt1 axis for NAFLD treatment [72]. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.